📰 Michaelk Schultz News
Michaelk Schultz News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Michaelk Schultz. Real-time updates on events, politics, business and more.
March 11, 2024
SEATTLE, March 11, 2024 -- Perspective Therapeutics, Inc. , a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that...
February 1, 2024
Signs a World-Wide Exclusive License with Stony Brook University for a Novel Platform that can Enhance Radionuclide TargetingReceives up to $2.4M ...
November 14, 2023
SEATTLE, Nov. 14, 2023 -- Perspective Therapeutics, Inc. , today announced third quarter financial results for the period ended September 30, 2023 and provided recent business highlights.. ...
August 30, 2023
RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 -- Perspective Therapeutics, Inc. , today announced that it will have two presentations at the upcoming World Molecular Imaging Congress 2023,...
October 11, 2022
SBIR Phase II Grants bring the cumulative grant total to approximately $17 million from the National Institutes of Health and National Cancer InstituteCORALVILLE, IA / ACCESSWIRE / October 11, 2022 / Viewpoint
December 21, 2021
Optimized 203Pb/212Pb image-guided alpha-particle radionuclide therapy for SST2R expressing tumorsPreclinical data of VMT-??-NET demonstrated to significantly improve cell binding, tumor accumulation/retention
April 13, 2021
- Preclinical study evaluated melanocortin 1 receptor (MC1R) as a potential target for MC1R-targeted therapies for metastatic melanoma, the lead target of VMT01 - - Results indicate that MC1R-targeted
January 8, 2021
Viewpoint Molecular Targeting, Inc.: Viewpoint Molecular Targeting Announces Closing of Its Series A Financing with Proceeds of $13 Million ?? -NET into Phase 1 imaging studies beginning in 2021 and accelerate development of radioisotope production technologies CORALVILLE, IA / ACCESSWIRE / January 8, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging...